Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CDC25A | P30304 | 1/20 | 0.32 |
| ▸ | CDC25B | P30305 | 1/20 | 0.32 |
| ▸ | CDC25C | P30307 | 1/20 | 0.32 |
| ▸ | ELANE | P08246 | 1/20 | 0.32 |
| ▸ | CA12 | O43570 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NOX1 | Q9Y5S8 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24132855 | 1.00 | CA9 (0.33) | CA9CA2CDC25ACDC25BCDC25C | |
| SCHEMBL26048161 | 1.00 | CA9 (0.33) | CA9CA2CDC25ACDC25BCDC25C | |
| SCHEMBL26048155 | 1.00 | CA9 (0.33) | CA9CA2CDC25ACDC25BCDC25C | |
| SCHEMBL26048163 | 0.79 | ELANE (0.32) | CA9CA2ELANEMEN1KMT2A | |
| SCHEMBL26048158 | 0.79 | ELANE (0.32) | CA9CA2ELANEMEN1KMT2A | |
| SCHEMBL26048253 | 0.79 | ELANE (0.32) | CA9CA2ELANEMEN1KMT2A | |
| SCHEMBL26048257 | 0.76 | CYP19A1 (0.33) | ELANEMEN1KMT2A | |
| SCHEMBL26048162 | 0.76 | CYP19A1 (0.33) | ELANEMEN1KMT2A | |
| SCHEMBL26048156 | 0.76 | CYP19A1 (0.33) | ELANEMEN1KMT2A | |
| SCHEMBL12059117 | 0.76 | CA9 (0.40) | CA9CA2CA12MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260098021-A1 | Nitrosation Reagents and Methods | UNIV CALIFORNIA (US) | 2026-04-09 | — | — | US | disclosed |
| US-12459909-B2 | Nitrosation reagents and methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-11-04 | — | — | US | disclosed |
| US-20230242495-A1 | Nitrosation Reagents and Methods | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12459909-B2 | Nitrosation reagents and methods | NOS2, NOS1, NNMT | CA9 1640/4885CA2 2079/4885CDC25A 3904/4885 |
| US-20260098021-A1 | Nitrosation Reagents and Methods | TXN, CBR1, CBR3 | CA9 1717/4885CA2 3045/4885CDC25A 4259/4885 |
| US-20230242495-A1 | Nitrosation Reagents and Methods | NOS2, NOS1, NNMT | CA9 1640/4885CA2 2079/4885CDC25A 3904/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.